Register to get unlimited Level 2

Company Announcements

Sale and Purchase Agreement Signed

Related Companies

RNS Number : 3582D
Ark Therapeutics Group PLC
28 January 2015
 



 

 

ARK THERAPEUTICS GROUP PLC

 

Sale and Purchase Agreement Signed

 

 

London, UK, 28 January 2015 (LSE: AKT):  Ark Therapeutics Group plc ("Ark" or the "Company") announces that, as foreshadowed in the Company's announcement and in its circular to shareholders, in each case dated 21 November 2014, it has entered into a share sale and purchase agreement with Rajan Uppal, Dominic Tonner and Berkeley Burke Trustee Company Limited to acquire 75.8% of the issued share capital of Premier Veterinary Group Limited ("PVG"). The aggregate consideration payable to all PVG shareholders is £3,731.18 in cash. The sellers have invoked the drag-along provisions contained in PVG's articles of association to enable the Company to acquire the entire issued share capital of PVG.

 

Completion of the acquisition is scheduled to occur on 5 February 2015. The Company's shares will remain suspended until further notice but, as set out in the circular of 21 November 2014, it is the intention of the Company to publish a prospectus and to seek readmission of the Company's shares on the standard segment of the Official List and to trading on the Main Market of the London Stock Exchange. A further announcement will be made in due course. 

 

 

For further information please contact:

 

Ark Therapeutics Group plc                                         Tel:  +44(0)203 755 5160

 

Iain G Ross, Non-Executive Chairman

Susan Steven, Non-Executive Director

 

 

This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding Ark's financial position, business strategy, plans and objectives of management for future operations, and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond Ark's control that could cause the actual results, performance or achievements of Ark to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding Ark's present and future business strategies and the environment in which Ark will operate in the future. These forward-looking statements speak only as at the date of this announcement. Ark expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in Ark's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, readers are cautioned not to rely on any forward-looking statement.

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLIFFALTITFIE

Top of Page